• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Arrowhead Pharmaceuticals Inc.

    7/29/25 11:20:42 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARWR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 8)


    Arrowhead Pharmaceuticals Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    04280A100

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    04280A100


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    142,962.00
    7Sole Dispositive Power

    15,243,118.00
    8Shared Dispositive Power

    281,954.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    15,525,072.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    11.24 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Arrowhead Pharmaceuticals Inc
    (b)Address of issuer's principal executive offices:

    177 East Colorado Blvd, Suite 700, Pasadena, CA, 91105
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd., Malvern, PA 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    04280A100
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    15525072
    (b)Percent of class:

    11.24  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    142962

     (iii) Sole power to dispose or to direct the disposition of:

    15243118

     (iv) Shared power to dispose or to direct the disposition of:

    281954

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:07/29/2025
    Get the next $ARWR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARWR

    DatePrice TargetRatingAnalyst
    6/5/2024$31.00Neutral
    Goldman
    12/4/2023$29.00Buy
    BofA Securities
    9/19/2023$33.00Neutral
    Citigroup
    7/21/2023Outperform
    TD Cowen
    5/12/2023$40.00Outperform → Market Perform
    SVB Securities
    4/26/2023$80.00Outperform
    SMBC Nikko
    4/12/2023$21.00 → $35.00Market Perform → Outperform
    SVB Securities
    3/21/2023$27.00Mkt Perform
    Bernstein
    More analyst ratings

    $ARWR
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Arrowhead Pharmaceuticals Inc.

    SCHEDULE 13D/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

    8/15/25 5:28:19 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Arrowhead Pharmaceuticals Inc.

    SCHEDULE 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

    8/14/25 7:07:30 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Arrowhead Pharmaceuticals Inc.

    144 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

    8/13/25 8:55:11 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARWR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

    - Arrowhead has elected to receive approximately $50 million worth of Arrowhead common stock from Sarepta, which will be placed into treasury and reduce the number of Arrowhead shares outstanding - The remainder of the recently earned $100 million milestone, or approximately $50 million, will be received in cash - Sarepta's remaining holdings of Arrowhead stock were sold today in a separate negotiated block trade Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has elected to receive approximately $50 million worth of Arrowhead common stock and approximately $50 million in cash from Sarepta Therapeutics, satisfying the payment of a $100 million milestone owed to A

    8/13/25 4:10:00 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

    - Conference Call and Webcast Today, August 7, 2025, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is hosting a conference call today, August 7, 2025, at 4:30 p.m. ET to discuss the results. "Arrowhead continues to achieve strong execution in discovery, clinical and regulatory, and business development. Our pipeline has become quite mature, with four Arrowhead discovered candidates currently in pivotal Phase 3 studies. In addition, our commercial buildout is designed to make us launch ready on day one, should plozasiran receive regulatory approval on the November 18, 2025

    8/7/25 4:01:00 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

    - Sanofi to pay $130 million upfront and up to $265 million in potential regulatory milestones to Visirna Therapeutics, a majority-owned subsidiary of Arrowhead, which was previously granted rights to investigational plozasiran in Greater China - Sanofi will receive an exclusive license to develop and commercialize investigational plozasiran in Greater China from Visirna Therapeutics, offering potential treatment to people living with elevated triglycerides Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead created to develop and commercialize four of A

    8/1/25 6:30:00 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARWR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Arrowhead with a new price target

    Goldman initiated coverage of Arrowhead with a rating of Neutral and set a new price target of $31.00

    6/5/24 7:11:50 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities initiated coverage on Arrowhead with a new price target

    BofA Securities initiated coverage of Arrowhead with a rating of Buy and set a new price target of $29.00

    12/4/23 7:19:37 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Arrowhead with a new price target

    Citigroup initiated coverage of Arrowhead with a rating of Neutral and set a new price target of $33.00

    9/19/23 7:26:13 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARWR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Hamilton James C sold $200,000 worth of shares (10,000 units at $20.00), decreasing direct ownership by 4% to 262,122 units (SEC Form 4)

    4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

    8/15/25 5:59:02 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Apel Daniel Joseph claimed ownership of 101,200 shares (SEC Form 3)

    3 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

    8/12/25 5:49:57 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Anzalone Christopher Richard sold $1,533,337 worth of shares (141,122 units at $10.87), decreasing direct ownership by 3% to 3,921,255 units (SEC Form 4)

    4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

    4/11/25 6:20:07 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARWR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    $ARWR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ARWR
    Leadership Updates

    Live Leadership Updates

    View All

    SEC Form SC 13G filed by Arrowhead Pharmaceuticals Inc.

    SC 13G - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

    11/14/24 9:38:25 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Arrowhead Pharmaceuticals Inc.

    SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

    10/16/24 9:15:20 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Arrowhead Pharmaceuticals Inc. (Amendment)

    SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

    4/10/24 2:03:52 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lu Hongbo bought $82,990 worth of shares (3,000 units at $27.66), increasing direct ownership by 10% to 33,680 units (SEC Form 4)

    4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

    3/20/24 7:06:58 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that, effective May 13, 2025, Arrowhead's Chief Financial Officer, Ken Myszkowski, will retire after 16 years of service to the company and will be succeeded by Daniel Apel, who has been appointed as the company's new Chief Financial Officer. Mr. Myszkowski will continue to serve as an employee adviser to assist and facilitate an effective transition. "Ken has been a valuable member of the Arrowhead team, and he retires at a time of great financial strength for the company. The finance organization that Ken built over the years is very capable and provides strong support to our ambitious development and commercialization plans.

    4/15/25 4:00:00 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600

    NEW YORK, Jan. 22, 2025 /PRNewswire/ -- Guidewire Software Inc. (NYSE:GWRE) will replace Arrowhead Pharmaceuticals Inc. (NASD: ARWR) in the S&P MidCap 400, and Arrowhead Pharmaceuticals will replace Barnes Group Inc. (NYSE:B) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, January 27. S&P 500 constituent Apollo Global Management Inc. (NYSE:APO) is acquiring Barnes Group in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector January 27, 2025 S&P MidCap 400 Addition Guidewi

    1/22/25 5:54:00 PM ET
    $APO
    $ARWR
    $B
    Investment Managers
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Turnstone Biologics Appoints William Waddill to its Board of Directors

    SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. "I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone," said Sammy Farah, M.B.A.,

    4/16/24 9:00:00 AM ET
    $ANNX
    $ARWR
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ARWR
    Financials

    Live finance-specific insights

    View All

    Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

    - Arrowhead has elected to receive approximately $50 million worth of Arrowhead common stock from Sarepta, which will be placed into treasury and reduce the number of Arrowhead shares outstanding - The remainder of the recently earned $100 million milestone, or approximately $50 million, will be received in cash - Sarepta's remaining holdings of Arrowhead stock were sold today in a separate negotiated block trade Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has elected to receive approximately $50 million worth of Arrowhead common stock and approximately $50 million in cash from Sarepta Therapeutics, satisfying the payment of a $100 million milestone owed to A

    8/13/25 4:10:00 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

    - Conference Call and Webcast Today, August 7, 2025, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is hosting a conference call today, August 7, 2025, at 4:30 p.m. ET to discuss the results. "Arrowhead continues to achieve strong execution in discovery, clinical and regulatory, and business development. Our pipeline has become quite mature, with four Arrowhead discovered candidates currently in pivotal Phase 3 studies. In addition, our commercial buildout is designed to make us launch ready on day one, should plozasiran receive regulatory approval on the November 18, 2025

    8/7/25 4:01:00 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results

    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on August 7, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 third quarter ended June 30, 2025. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at https://register-conf.media-server.com/register/BI3955ca6732974874b0bc0ac323811a7f. Once registered, you w

    7/21/25 4:01:00 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care